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Objectives We aimed to investigate the pathophysiology of peripheral arterial disease (PAD) by examining magnetic reso-
nance imaging (MRI) and spectroscopic (MRS) correlates of functional capacity.
Background Despite the high prevalence, morbidity, and cost of PAD, its pathophysiology is incompletely understood.
Methods Eighty-five patients (age 68  10 years) with mild-to-moderate PAD (ankle-brachial index 0.69  0.14) had their
most symptomatic leg studied by MRI/MRS. Percent wall volume in the superficial femoral artery was measured with
black blood MRI. First-pass contrast-enhanced MRI calf muscle perfusion and 31P MRS phosphocreatine recovery
time constant (PCr) were measured at peak exercise in calf muscle. All patients underwent magnetic resonance an-
giography (MRA), treadmill testing with maximal oxygen consumption measurement, and a 6-min walk test.
Results Mean MRA index of number and severity of stenoses was 0.84  0.68 (normal 0), % wall volume 74  11%
(normal 46  7%), tissue perfusion 0.039  0.015 s1 (normal 0.065  0.013 s1), and PCr 87  54 s (nor-
mal 34  16 s). MRA index, % wall volume, and ankle-brachial index correlated with most functional measures.
PCr was the best correlate of treadmill exercise time, whereas calf muscle perfusion was the best correlate of
6-min walk distance. No correlation was noted between PCr and tissue perfusion.
Conclusions Functional limitations in PAD are multifactorial. As measured by MRI and spectroscopy, atherosclerotic plaque
burden, stenosis severity, tissue perfusion, and energetics all play a role. However, cellular metabolism is uncou-
pled from tissue perfusion. These findings suggest a potential role for therapies that regress plaque, increase
tissue perfusion, and/or improve cellular metabolism. (Comprehensive Magnetic Resonance of Peripheral Arte-
rial Disease; NCT00587678) (J Am Coll Cardiol 2009;54:628–35) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.080t
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aeripheral arterial disease (PAD) affects over 8 million Amer-
cans, and its prevalence is expected to rise as the population
ges (1). Apart from its strong association with cardiovascular
ortality, PAD itself carries significant morbidity (2) and
ealth care costs (3). Patients with PAD suffer from progres-
ive functional decline and impaired quality of life (4,5).
Despite the high prevalence, cost, and morbidity of lower-
xtremity PAD, there are few effective medical therapies for
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irginia, Charlottesville, Virginia. Supported by National Heart, Lung, and Blood
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or Research Resources, and NIBIB T32 EB003841 (to Drs. Anderson and West).
rs. Epstein, Meyer, Hagspiel, and Kramer receive research support from Siemens
edical Solutions.i
Manuscript received August 6, 2008; revised manuscript received January 6, 2009,
ccepted January 14, 2009.he diseased limb, in part due to 2 factors. First, the patho-
hysiology of PAD is complex and incompletely understood.
hile the obstruction of blood flow due to large vessel
therosclerosis is critical, the degree of hemodynamic impair-
ent does not consistently relate to functional limitation (6).
See page 636
hus, factors independent of blood flow and downstream from
he obstruction are believed to play an important role. Sec-
ndly, the current gold standard for testing the efficacy of
herapeutic interventions, the exercise treadmill test (7), often
acks standardization and is plagued by intrapatient variability
nd a significant placebo response.
Therefore, we aimed to further examine the pathophys-
ology of PAD and its primary clinical manifestation,
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August 11, 2009:628–35 Determinants of Functional Capacity in PADlaudication, by determining the relationship between large
essel obstruction, atherosclerotic plaque burden, tissue perfu-
ion, cellular metabolism, and functional capacity. To accom-
lish this, we used newly developed magnetic resonance im-
ging (MRI) and spectroscopy (MRS) methods to assess
therosclerotic plaque burden (8) and exercise measures of calf
uscle perfusion (9) and metabolism (10) in patients with
ild-to-moderate PAD. We also examined their relationship
o functional capacity.
ethods
tudy population. Subjects between the ages of 30 and 85
ears with symptoms of intermittent claudication and an
nkle-brachial index (ABI) between 0.4 and 0.9 were
ligible for this study. The protocol was approved by the
uman Investigation Committee at the University of Vir-
inia Health System, and all participants signed informed
onsent. Subjects with rest pain, critical limb ischemia, or a
ontraindication to MRI were excluded as were those with
omorbidities that severely limited their ability to perform a
alking treadmill test. Normal human subjects without risk
actors for atherosclerosis were recruited from the commu-
ity to serve as control subjects for calf muscle perfusion
easures.
tudy protocol. The study was divided over 2 days to allow
ufficient time between exercise portions of the protocol to
void fatigue and/or ischemic pre-conditioning. Patients
ere admitted overnight to the General Clinical Research
enter. Due to time constraints, only the most symptomatic
eg was studied by MRI/MRS. Entry ABIs were obtained at
he University of Virginia vascular laboratory using standard
echniques.
agnetic resonance protocols. MRI protocols were com-
leted on an Avanto 1.5-T scanner and MRS protocols on
Sonata 1.5-T scanner (both Siemens Medical Solutions,
rlangen, Germany).
ALL VOLUME. Wall volume in 15 to 20 cm of the super-
cial femoral artery was assessed as previously described (8)
sing a custom-built surface coil array placed over the thigh
f the subject’s most symptomatic leg and a fat-suppressed
ultislice turbo spin echo pulse sequence (Fig. 1A). Wall
olume, defined as total vessel area minus lumen area
ultiplied by the slice thickness, was measured with
esselMASS software (University of Leiden, Leiden, the
etherlands). Percentage wall volume was calculated by
ividing the wall volume by the total vessel volume (wall 
umen) (11).
ALF MUSCLE PERFUSION. Calf muscle perfusion measured at
eak exercise was performed with a magnetic resonance-
ompatible foot pedal ergometer using first-pass contrast-
nhanced imaging as previously described (9) (Fig. 1C).
articipants performed pedal ergometry at a steady rate (10 to
2 rpm) until exhaustion and/or limiting symptoms developed.
adopentetate dimeglumine 0.1 mmol/kg (Magnevist, Berlex, tontville, New Jersey) was imme-
iately infused and imaging com-
enced. Time intensity curves
ere generated with Argus soft-
are (Siemens Medical Solutions)
or regions of interest in the calf
uscle and input artery (typically
he popliteal). The slope of the
ime intensity curve of signal nor-
alized to the proton density from
he calf muscle group with the
reatest signal intensity was de-
ned as tissue perfusion. To assess
icrovascular blood flow, tissue
erfusion was indexed to macro-
ascular blood flow into the calf by
ividing it by the slope of the
rterial input curve to obtain a
erfusion index (9).
HOSPHOCREATINE RECOVERY. Phosphocreatine recovery
ime constant (PCr) was measured as previously described
10) by 31phosphorus MRS during recovery from peak
xercise using a single-pulse, surface coil localized, 512 ms
ree induction decay acquisition with 20 averages centered
n the midcalf. PCr was then calculated using a monoex-
onential fit of phosphocreatine concentration versus time,
eginning at cessation of exercise (Fig. 1D). Calf muscle pH
t end-exercise was measured as previously described (10).
AGNETIC RESONANCE ANGIOGRAPHY (MRA). Gadopentetate
imeglumine (0.2 mmol/kg) enhanced MRA from the
bdominal aorta to the foot was performed with a moving
able/bolus chase technique in 3 stations (64 to 104 slices,
eld of view 500 mm, repetition time 2.5 to 3.0, echo time
.0 to 1.1, flip angle 20 to 25°, voxel size 1.6 to 2.0 mm 
.0 to 1.3 mm  1.0 to 1.5 mm) (Fig. 1B). Image analysis
as performed by 2 experienced observers by visual consen-
us using 2 different grading schemes (12,13). First, the
rterial tree of the leg of interest was divided into 16
egments from the distal aorta to the runoff vessels. A
-point ordinal scale (0 for 0% to 19% diameter stenosis, 1
or 20% to 49%, 2 for 50% to 74%, 3 for 75% to 99%, and
for total occlusion) was used to grade each segment. The
otal score was then indexed to the total number of
egments (MRA index) (12). The runoff index (13) then
ssesses the resistance to blood flow by accounting for the
ength of occlusion and weighting each segment by its
ontribution to calf muscle perfusion.
unctional measures. 6-MIN WALK DISTANCE. Subjects
alked up and down a 100-ft corridor for 6 min, and walking
istance and initial claudication distance were recorded.
READMILL TEST. Under the supervision of a physician and
n exercise physiologist, subjects underwent a standardized
raded Skinner-Gardner exercise treadmill test (14). Pa-
Abbreviations
and Acronyms
ABI  ankle-brachial index
CRP  C-reactive protein
MRA  magnetic
resonance angiography
MRI  magnetic resonance
imaging
MRS  magnetic
resonance spectroscopy
PAD  peripheral arterial
disease
PCr  phosphocreatine
recovery time constant
VO2  maximal oxygen
consumptionients had maximal oxygen consumption (VO2) and electro-
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Determinants of Functional Capacity in PAD August 11, 2009:628–35ardiogram monitoring during the exam. Metabolic mea-
ures were collected using standard open circuit spirometry
Viasys 229, Yorba Linda, California). The test was termi-
ated by the participant at volitional exhaustion, due to
ymptom limiting claudication or after 20 min. Total treadmill
xercise time, time to claudication, and symptom-limited VO2
ere measured. Post-exercise ABI was measured.
HYSICAL ACTIVITY QUESTIONNAIRE. Physical activity was
ssessed using the Aerobics Center Longitudinal Study
hysical Activity Questionnaire (15) modified for interview.
hysical activity was calculated as metabolic equivalent
ours per week using the Compendium of Physical Activ-
ties (16). Energy expenditure per week was estimated.
nflammatory markers and fractionated lipids. Baseline
ipids were measured. High sensitivity C-reactive protein
CRP) was assayed on a solid-phase, chemiluminescent
mmunometric analyzer (Immulite 2000, Diagnostics Prod-
cts Corp., Los Angeles, California). Interleukin-10 and
umor necrosis factor-alpha were assayed by quantitative
Figure 1 MR Plaque and Calf Muscle Perfusion Images, MR An
and MRS Phosphocreatine Recovery Curve All From th
(A) High resolution black blood magnetic resonance (MR) image of the superficial
vessel wall by a black arrow. Note the large amount of atherosclerotic plaque in t
a severe stenosis in the proximal left superficial femoral artery, which corresponds
the calf muscle in cross section. Note the heterogeneous signal intensity. Arrows
trast enhancement (i.e., perfusion). (D) The graph is a plot of phosphocreatine rec
on the x axis. The phosphocreatine recovery time constant (PCr) is calculated usin
PAD  peripheral arterial disease.andwich enzyme immunoassays. etatistics. All patients’ baseline characteristics, MRI, and
unctional measures were presented as mean (SD) for
ontinuous variables and n (%) for categorical variables.
tandard statistical tests including the Shapiro-Wilk test
nd the normal probability plot were used to check the
ormality assumption for continuous variables. Bivariate
elationships between each factor and outcomes were exam-
ned using either Pearson’s correlation coefficient or Spear-
an’s rank correlation coefficient. Multivariable regression
odels were fit to examine the relationship between the
unctional capacity outcomes and the selected MRI factors
ncluding MRA index, PCr, tissue perfusion, and % wall
olume. F-tests were used to identify the MRI factors that
ere strongly related with different functional outcomes. All
tatistical analyses were performed using SAS version 9.1.3
SAS Institute, Cary, North Carolina).
esults
ighty-seven patients with mild-to-moderate PAD were
am,
me Patient With PAD
l artery in cross section. The vessel lumen is denoted by a gray arrow and the
sel wall. (B) MR angiogram of the superficial femoral artery. The arrow denotes
e vessel wall image in A. (C) Post-exercise contrast-enhanced peak perfusion of
the muscle groups (anterior tibialis and soleus muscles) with the greatest con-
with relative phosphocreatine concentration on the y axis and time in seconds
ono-exponential fit of this data. MRS  magnetic resonance spectroscopy;giogr
e Sa
femora
he ves
to th
depict
overy
g a mnrolled; 2 patients withdrew before completion of the MRI
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August 11, 2009:628–35 Determinants of Functional Capacity in PADue to claustrophobia, leaving 85 patients for data analysis.
ll 85 patients completed the 6-min walk test, while 83
ompleted the treadmill test. Percent wall volume, MRA
ndex, and runoff index data were obtained for all 85
atients, PCr from 83 patients, tissue perfusion from 80
atients, and perfusion index from 77 patients. Missing data
as due to either technical problems with data acquisition
r failure of the patient to complete the exercise. Seven
ormal subjects (age 47  5 years, 4 men) made up the
ohort of control subjects for perfusion measures.
Table 1 describes the baseline characteristics of the
atient population. The ranges for age, entry ABI, and body
ass index were 41 to 82, 0.36 to 0.90, and 17.1 to 53.3,
espectively. Women and non-Caucasians comprised 44%
nd 32% of the population, respectively. Of the 19 patients
ho had prior revascularization, 12 revascularizations were
f the leg studied by MRI. Of those 12, 9 had an iliac stent.
he remaining 3 had an aorta-femoral, femoral-femoral, or
emoral-popliteal artery bypass. Table 2 lists the results of
RI and functional measures, as well as the self-reported
hysical activity questionnaire and laboratory values. For
eference, values from normal subjects for the MRI mea-
ures are as follows: % wall volume  45.8  7.0% (17),
issue perfusion  0.065  0.013 s1, perfusion index 
.69  0.17 (9), and PCr  34  16 s (10). Normal values
or the MRA are assumed (runoff index 4, MRA index
). The relationships between the noninvasive measures
ssessed by either Pearson’s correlation coefficient or Spear-
an’s rank correlation coefficient are depicted in Table 3.
aseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Age, yrs 68.3  10.3
ABI 0.69  0.14
Exercise ABI 0.46  0.28
Body mass index, kg/m2 29.1  6.6
Men 48 (56)
Prior revascularization 19 (22)
Leg of interest 12 (14)
Race
White 58 (68)
Black 19 (22)
Other 8 (9)
Risk factors
Current smoker 41 (48)
Diabetes mellitus 27 (32)
Hypertension 73 (86)
History of coronary artery disease 62 (73)
Hypercholesterolemia 52 (61)
Medications
Aspirin/clopidogrel 61 (72)
Angiotensin-converting enzyme
inhibitor or receptor blocker
53 (62)
Beta-blocker 34 (40)
Cilastazol/pentoxyfiline 11 (13)
Statin 41 (48)s
alues are mean  SD or n (%).
ABI  ankle brachial index.he ABI correlated with each MRI/MRS measure as did
he MRA index. Of note, PCr did not correlate with tissue
erfusion or perfusion index (Fig. 2).
Table 4 shows the relationship between functional per-
ormance and the noninvasive measures. All noninvasive
easures correlated with treadmill exercise time, except for
issue perfusion and end-exercise pH. The individual cor-
elations between tissue perfusion and 6-min walk time and
Cr with treadmill exercise time are shown in Figures 3 and 4,
espectively. All noninvasive measures other than PCr and
erfusion demonstrated correlation to functional perfor-
ance as measured by VO2 (Table 4). Using a model that
ncluded tissue perfusion, % wall volume, PCr, and MRA
ndex, the F-test identified PCr as being significantly related to
he logarithm of treadmill exercise time (F  5.59, p  0.02),
issue perfusion with 6-min walk distance (F  7.61, p 
.01), and % wall volume with VO2 (F  4.19, p  0.05).
When the relationship between baseline clinical charac-
eristics and noninvasive and functional measures were
xamined, older age correlated with higher MRA index (r
.34, p  0.01) and lower tissue perfusion (r  0.32, p 
.05) and perfusion index (r  0.25, p  0.05), as well as
RI, Functional, and Laboratory ResultsTable 2 MRI, Functional, and Laboratory Results
Mean (SD) Range
MRI measures*
Runoff index 14.0 (6.9) 4–37.5
MRA index 0.84 (0.68) 0–2.81
PCr, s 86.9 (54.4) 20.9–250.0
End-exercise pH 7.02 (0.10) 6.74–7.26
Tissue perfusion, s1 0.039 (0.015) 0.012–0.078
Perfusion index 0.47 (0.17) 0.15–0.85
% wall volume 74 (11) 50–100
Functional measures
Treadmill exercise time, s 505 (345) 35–1,260
Time to claudication, s 222 (189) 42–1,200
6-min walk distance, ft 1,007 (394) 37–1,817
6-min claudication distance, ft 458 (246) 75–1,241
VO2, ml/kg/min 12.5 (4.0) 3.8–22.3
Self-reported function
Energy expenditure/week, kcal 9,416 (11,192) 47–78,028
Metabolic hours equivalent/week 104 (106) 0.3–682
Laboratory measures
Total cholesterol, mg/dl 182 (44) 78–299
LDL, mg/dl 110 (36) 25–217
HDL, mg/dl 43 (13) 18–76
Tryglycerides, mg/dl 158 (103) 42–694
Lipoprotein(a), mg/dl 7.3 (4.6) 2.0–27.0
CRP, mg/dl 3.8 (6.2) 0.04–32.6
IL-10, pg/ml 7.0 (27.1) 2.0–246.4
TNF-alpha, pg/ml 3.5 (3.5) 1.0–27.8
For reference, normal values for the magnetic resonance imaging (MRI) measures are runoff
ndex  4, magnetic resonance angiography (MRA) index  0, % wall volume  46  7% (17),
issue perfusion  0.065  0.0133, perfusion index  0.69  0.17 (9), and phosphocreatine
ecovery time constant (PCr)  34  16 s (10).
CRP  C-reactive protein; HDL  high-density lipoprotein; IL  interleukin; LDL  low-density
ipoprotein; TNF  tumor necrosis factor; VO2  maximal oxygen consumption.horter treadmill exercise time (r  0.30, p  0.01) and
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Determinants of Functional Capacity in PAD August 11, 2009:628–35-min walk distance (r  0.36, p  0.001). Non-
aucasian ethnicity was associated with a higher MRA
ndex (r  0.28, p  0.01) and lower perfusion index (r 
0.32, p  0.01). Female sex correlated with higher wall
olume (r  0.28, p  0.05), and lower perfusion index and
O2 (r  0.25, p  0.05 for both).
A history of hypertension related to a higher % wall
olume (r  0.28, p  0.05). Prior revascularization was
ssociated with higher % wall volume (r  0.22, p  0.05),
RA index (r  0.26, p  0.05), and runoff index (r 
.32, p  0.01) and a worse 6-min walk distance and VO2
r  0.25, p  0.05 for both). The presence of diabetes
elated to a worse VO2(r  0.22, p  0.05). CRP was the
nly measured serum or inflammatory marker to relate to
Figure 2 Lack of Correlation Between PCr and Perfusion
Correlation between phosphocreatine recovery time constant (PCr) and tissue
perfusion demonstrating the lack of significant relationship between the 2
parameters (y  7.52  106  0.38, r  0.02, p  0.82).
elationship Between Noninvasive MeasuresTable 3 Relationship Between Noninvasive Measures
Runoff
Index MRA Index PCr
End-Exerc
pH
Runoff index X
MRA index r 0.76
p 0.0001
X
PCr r 0.34
p 0.05
r 0.39
p 0.001
X
End-exercise pH NS NS NS X
Tissue perfusion NS NS NS NS
Perfusion index NS r0.26
p 0.05
NS NS
% wall volume r 0.39
p 0.001
r 0.46
p 0.0001
NS r 0.25
p 0.05
ABI r0.32
p 0.01
r0.40
p 0.001
r0.32
p 0.01
NS
Exercise ABI r0.21
p 0.05
r0.25
p 0.05
r0.47
p 0.001
NS
The perfusion index is derived from the tissue perfusion and thus the correlation is not applicabl
ABI ankle brachial index; other abbreviations as in Table 2.wny functional measure as it had a negative correlation with
-min walk distance (r  0.25, p  0.05).
When the relationship between self-reported physical
ctivity levels and noninvasive measures were examined,
oth physical activity and energy expenditure correlated
ith % wall volume (r  0.25, p  0.05 for both).
stimated physical activity correlated with the 6-min walk
istance (r  0.27, p  0.05) and time to claudication (r 
.30, p  0.01).
iscussion
his study used MRI and MRS to further elucidate the
ultifactorial pathophysiology of claudication. We found
hat the severity of macrovascular obstruction, atheroscle-
otic plaque burden, reduced tissue perfusion, and abnormal
nergy metabolism all relate to functional limitation in
atients with claudication. Another important finding is
hat the PCr of calf muscle does not correlate with calf
uscle perfusion, suggesting that cellular metabolism im-
acts exercise performance but is uncoupled from tissue
erfusion. Taken together, these MRI/MRS measures allow
n integrative assessment of large vessel atherosclerosis,
lood flow, and cellular metabolism, which each individu-
lly contribute to functional capacity in PAD.
The pathophysiology of claudication is complex and
ncompletely understood. In prior studies, the degree of flow
imitation has not correlated with functional impairment.
BI has not correlated with lower extremity functional
trength (18). Maximal calf blood flow measured by strain
auge plethysmography does not predict treadmill walking
istance (19). Furthermore, when patients with PAD un-
ergo exercise training, their functional capacity and calf
lood flow improve, but changes in flow have not correlated
Tissue
Perfusion
Perfusion
Index
% Wall
Volume ABI
Exercise
ABI
X
* X
NS NS X
r 0.33
p 0.01
r 0.31
p 0.01
r0.26
p 0.01
X
r 0.30
p 0.01
NS NS r 0.74
p 0.0001
Xiseith changes in function (20).
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August 11, 2009:628–35 Determinants of Functional Capacity in PADIn the present study, calf muscle blood flow at peak
xercise, as measured by first-pass contrast-enhanced MRI,
orrelated with 6-min walk distance. The discrepancy be-
ween previous studies and the present study can likely be
xplained by the techniques used to measure calf muscle
erfusion. The prior studies measured gross calf muscle
lood flow. With the ability to visualize the individual
uscle groups used in exercise, inactive muscles and intra-
ascular flow can be excluded, allowing for a more direct
nalysis of maximal end organ tissue perfusion.
Factors independent of blood flow and intrinsic to the
keletal muscle likely play a role in the functional limitations
een in PAD. Patients with PAD have impaired mitochon-
rial function (21,22) as mitochondria are morphologically
bnormal and are increased in number proportionally to the
Figure 3 Correlation Between Perfusion and 6-Min Walk
Correlation demonstrating positive relationship between tissue perfusion
and 6-min walk distance (y  8857  672, r  0.32, p  0.01).
elationship Between Imaging and Functional ParametersTable 4 Relationship Between Imaging and Functional Parame
Treadmill
Exercise Time
Time to
Claudication
Runoff index r0.30
p 0.01
r0.23
p 0.06
MRA index r0.31
p 0.01
r0.24
p 0.05
PCr r0.22
p 0.05
NS
End-exercise pH NS NS
Tissue perfusion NS NS
Perfusion Index NS NS
% wall volume r0.32
p 0.01
r0.27
p 0.05
ABI r 0.38
p 0.001
NS
Exercise ABI r 0.28
p 0.01
r 0.26
p 0.05
BI  ankle brachial index; VO2  maximal oxygen consumption; other abbreviations as in Tableeverity of occlusive disease (23). Phosphocreatine recovery
ate post-exercise, an index of mitochondrial function, is
ignificantly diminished in PAD (10). In the present study,
Cr correlated inversely with treadmill exercise time, lend-
ng credence to the concept that mitochondrial dysfunction
lays a role in the exercise limitation of PAD.
One of the aims of this study was to further explore the
elationship between tissue perfusion and mitochondrial
unction (cellular metabolism). Previous studies that exam-
ned this relationship have inferred blood flow from angio-
raphic findings and the ABI (24) or examined mitochon-
rial function under conditions of unchallenged blood flow
25). We demonstrated no correlation between contrast-
nhanced measures of tissue perfusion with PCr, supporting
Figure 4 Correlation Between PCr and Exercise Time
Correlation demonstrating the inverse relationship between phosphocreatine
recovery time constant (PCr) and treadmill exercise time (y  2.1  680,
r  0.22, p  0.05).
6-Min Walk
Distance
6-Min Distance to
Claudication VO2
r0.35
p 0.001
r0.28
p 0.05
r0.36
p 0.001
r0.33
p 0.01
r0.30
p 0.05
r0.36
p 0.001
NS NS NS
NS NS r0.28
p 0.05
r 0.32
p 0.01
NS NS
NS NS NS
r0.30
p 0.01
NS r0.38
p 0.001
r 0.32
p 0.01
r 0.28
p 0.05
r 0.26
p 0.05
NS NS NSters
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Determinants of Functional Capacity in PAD August 11, 2009:628–35he notion that mitochondrial impairment in PAD is
ncoupled from reduced blood flow. However, one reason
or the lack of correlation could be that PCr is measured
rom a slab of tissue across the entire calf whereas perfusion
s measured in specific regions of interest in the calf muscle.
Several measures were identified in the present study that
orrelate with exercise performance and may be suitable as
urrogate measures of functional capacity in PAD therapeu-
ic trials. Currently, the accepted primary end point for new
laudication therapies is an improvement in exercise perfor-
ance measured by treadmill testing (7). Some have spec-
lated that the failure of many investigational therapies to
how benefit may be due to the known placebo response and
ignificant intrapatient variability (26). A recent study has
hown that simple office-based measures of functional
apacity can predict mortality beyond that of the ABI (27).
onger follow-up is required to demonstrate whether an
mprovement in any of the identified imaging end points
ranslate into clinical improvement. Additional techniques
uch as 1H MRS to assess ischemia-induced reoxygenation
ay also offer potential in this regard (28).
Patient characteristics associated with worse imaging and
unctional performance in the present study included older
ge, non-Caucasian ethnicity, and female sex. Age is a
nown risk factor for the presence of PAD (29) as is
frican-American race (30), and both were shown to be
ssociated with greater atherosclerosis burden and worse
issue perfusion at peak exercise in this study. We investi-
ated the association between lipids and inflammatory
arkers with functional status. Apart from the modest
elationship of CRP with the 6-min walk distance, which
as been previously demonstrated (31), no other measured
aboratory marker correlated with any functional measure.
RP did not correlate with MRA index or % wall volume,
uggesting that the relationship with function is not merely
reflection of atherosclerosis burden.
tudy limitations. Our patient population excluded those
ith PAD who were asymptomatic, had critical limb
schemia, or had significant comorbid conditions. Thus, our
esults should not be generalized to these patient popula-
ions. PAD typically involves both lower extremities and
unctional capacity is dependent on both legs. However, in
ur study we only studied the most symptomatic leg due to
he practicality and time constraints of acquiring several
RI measures.
Collateral blood flow plays an important role in the
athophysiology of PAD. However, the spatial resolution of
RA allows detection of only a fraction of collateral vessels.
ndothelial function is abnormal in patients with peripheral
ascular disease (32). Its contribution to the pathophysiol-
gy of claudication has not been thoroughly investigated.
he present study did not include a measure of endothelial
unction.
Two of the methods in this study, MRI first-pass tissue
erfusion and MRA, utilize gadolinium-based contrast
gents. Recently the Food and Drug Administration has
1ssued a warning regarding the use of these agents in
atients with advanced kidney disease (33). To some extent
his may limit the use of these agents in patients with renal
ailure, although early hemodialysis may prevent the devel-
pment of this side effect (34).
linical implications. Despite the significant prevalence,
orbidity, and cost associated with PAD, there are few
ffective therapies, in part due to the incomplete understanding
f pathophysiology. In the present study, we have demon-
trated that the functional limitation seen in PAD patients is
ultifactorial. Abnormal mitochondrial function in PAD is
ndependent of tissue perfusion and it too correlates with
unctional impairment. These findings suggest a potential role
or therapies that regress plaque, increase tissue perfusion,
nd/or improve cellular metabolism.
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